Rhythm Pharmaceuticals (RYTM) Stock Analysis & Winston Score

Rhythm Pharmaceuticals is a biotech company that makes medicines for rare genetic diseases that cause severe obesity. Its main product is Imcivree (setmelanotide), a drug that targets specific gene mutations in the brain's hunger-signaling pathway. The company focuses on patients with conditions like POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome — diseases so rare that most patients go undiagnosed for years. Rhythm earns revenue by selling Imcivree directly to patients and specialty pharmacies, primarily in the United States and parts of Europe. The drug's 89% gross margin reflects the high pricing typical of rare-disease treatments, where small patient populations allow premium pricing. The company is still unprofitable as it spends heavily on research and expanding Imcivree's approved uses to additional rare genetic obesity conditions. The key growth driver is winning regulatory approvals for more gene variants, but the main risk is that the total addressable patient population remains very small, limiting how large the business can ultimately grow.